apellis pharmaceuticals inc - APLS
APLS
Close Chg Chg %
40.39 0.02 0.05%
Closed Market
40.41
+0.02 (0.05%)
Volume: 10.33M
Last Updated:
Apr 2, 2026, 4:00 PM EDT
Company Overview: apellis pharmaceuticals inc - APLS
APLS Key Data
| Open $40.38 | Day Range 40.35 - 40.48 |
| 52 Week Range 16.10 - 40.48 | Market Cap $5.17B |
| Shares Outstanding 127.83M | Public Float 104.43M |
| Beta -0.20 | Rev. Per Employee N/A |
| P/E Ratio 234.40 | EPS $0.17 |
| Yield 0.00% | Dividend N/A |
| EX-DIVIDEND DATE | SHORT INTEREST N/A |
| AVERAGE VOLUME 7.75M |
APLS Performance
| 1 Week | 138.13% | ||
| 1 Month | 101.35% | ||
| 3 Months | 56.26% | ||
| 1 Year | 102.35% | ||
| 5 Years | -6.67% |
APLS Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
21
Full Ratings ➔
About apellis pharmaceuticals inc - APLS
Apellis Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs. Its products include EMPAVELI and SYFOVRE. The company was founded by Candace Rose Depp, Pascal Deschatelets, Cedric Francois, and Alec Machiels on September 25, 2009 and is headquartered in Waltham, MA.
APLS At a Glance
Apellis Pharmaceuticals, Inc.
100 5th Avenue
Waltham, Massachusetts 02451-8703
| Phone | 1-617-977-5700 | Revenue | 1.00B | |
| Industry | Pharmaceuticals: Major | Net Income | 22.39M | |
| Sector | Health Technology | 2025 Sales Growth | 28.465% | |
| Fiscal Year-end | 12 / 2026 | Employees | 739 | |
| View SEC Filings |
APLS Valuation
| P/E Current | 234.397 |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | 145.708 |
| Price to Sales Ratio | 3.25 |
| Price to Book Ratio | 8.593 |
| Price to Cash Flow Ratio | 71.97 |
| Enterprise Value to EBITDA | 57.358 |
| Enterprise Value to Sales | 3.256 |
| Total Debt to Enterprise Value | 0.145 |
APLS Efficiency
| Revenue/Employee | 1,358,297.70 |
| Income Per Employee | 30,294.993 |
| Receivables Turnover | 2.741 |
| Total Asset Turnover | 1.024 |
APLS Liquidity
| Current Ratio | 3.136 |
| Quick Ratio | 2.696 |
| Cash Ratio | 1.446 |
APLS Profitability
| Gross Margin | 89.815 |
| Operating Margin | 5.522 |
| Pretax Margin | 2.402 |
| Net Margin | 2.23 |
| Return on Assets | 2.284 |
| Return on Equity | 7.479 |
| Return on Total Capital | 2.651 |
| Return on Invested Capital | 3.12 |
APLS Capital Structure
| Total Debt to Total Equity | 128.154 |
| Total Debt to Total Capital | 56.17 |
| Total Debt to Total Assets | 44.116 |
| Long-Term Debt to Equity | 100.936 |
| Long-Term Debt to Total Capital | 44.24 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Apellis Pharmaceuticals Inc - APLS
Collapse All in section
| All values USD millions. | 2022 | 2023 | 2024 | 2025 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| 75.42M | 396.59M | 781.37M | 1.00B | |
Sales Growth
| +13.31% | +425.83% | +97.02% | +28.46% | |
Cost of Goods Sold (COGS) incl D&A
| 7.12M | 60.21M | 117.72M | 102.24M | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 1.49M | 1.70M | 1.80M | 1.56M | |
Depreciation
| 1.49M | 1.70M | 1.80M | 1.56M | |
Amortization of Intangibles
| - | - | - | - | - |
COGS Growth
| +320.98% | +745.35% | +95.51% | -13.16% | |
Gross Income
| 68.30M | 336.38M | 663.64M | 901.55M | |
Gross Income Growth
| +5.28% | +392.51% | +97.29% | +35.85% | |
Gross Profit Margin
| +90.56% | +84.82% | +84.93% | +89.81% |
| 2022 | 2023 | 2024 | 2025 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 662.91M | 853.50M | 828.62M | 846.12M | |
Research & Development
| 387.24M | 354.39M | 327.57M | 295.85M | |
Other SG&A
| 275.68M | 499.11M | 501.05M | 550.26M | |
SGA Growth
| +10.27% | +28.75% | -2.91% | +2.11% | |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| - | - | 32.89M | 1.95M | - |
EBIT after Unusual Expense
| (627.50M) | (517.12M) | (166.93M) | 55.43M | |
Non Operating Income/Expense
| 8.63M | 20.21M | 10.60M | 13.01M | |
Non-Operating Interest Income
| 8.91M | 20.93M | 12.77M | 13.14M | |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Interest Expense
| 32.63M | 29.58M | 40.39M | 44.33M | |
Interest Expense Growth
| +146.40% | -9.33% | +36.54% | +9.74% | |
Gross Interest Expense
| 32.63M | 29.58M | 40.39M | 44.33M | |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| (651.50M) | (526.50M) | (196.72M) | 24.11M | |
Pretax Income Growth
| +12.67% | +19.19% | +62.64% | +112.26% | |
Pretax Margin
| -863.81% | -132.76% | -25.18% | +2.40% | |
Income Tax
| 669.00K | 2.13M | 1.16M | 1.72M | |
Income Tax - Current - Domestic
| 520.00K | 1.87M | 474.00K | 1.55M | |
Income Tax - Current - Foreign
| 149.00K | 263.00K | 688.00K | 172.00K | |
Income Tax - Deferred - Domestic
| - | - | - | - | - |
Income Tax - Deferred - Foreign
| - | - | - | - | - |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| (652.17M) | (528.63M) | (197.88M) | 22.39M | |
Minority Interest Expense
| - | - | - | - | - |
Net Income
| (652.17M) | (528.63M) | (197.88M) | 22.39M | |
Net Income Growth
| +12.62% | +18.94% | +62.57% | +111.31% | |
Net Margin Growth
| -864.70% | -133.29% | -25.32% | +2.23% | |
Extraordinaries & Discontinued Operations
| - | - | - | - | - |
Discontinued Operations
| - | - | - | - | - |
Net Income After Extraordinaries
| (652.17M) | (528.63M) | (197.88M) | 22.39M | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| (652.17M) | (528.63M) | (197.88M) | 22.39M | |
EPS (Basic)
| -6.146 | -4.4543 | -1.597 | 0.1775 | |
EPS (Basic) Growth
| +30.48% | +27.53% | +64.15% | +111.11% | |
Basic Shares Outstanding
| 106.11M | 118.68M | 123.91M | 126.14M | |
EPS (Diluted)
| -6.146 | -4.4543 | -1.597 | 0.1724 | |
EPS (Diluted) Growth
| +30.48% | +27.53% | +64.15% | +110.80% | |
Diluted Shares Outstanding
| 106.11M | 118.68M | 123.91M | 129.85M | |
EBITDA
| (593.13M) | (515.42M) | (163.18M) | 56.98M | |
EBITDA Growth
| -10.91% | +13.10% | +68.34% | +134.92% | |
EBITDA Margin
| -786.41% | -129.96% | -20.88% | +5.68% |
Snapshot
| Average Recommendation | HOLD | Average Target Price | 38.765 | |
| Number of Ratings | 21 | Current Quarters Estimate | -0.32 | |
| FY Report Date | 06 / 2026 | Current Year's Estimate | -1.116 | |
| Last Quarter’s Earnings | -0.30 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | 0.20 | Next Fiscal Year Estimate | -0.126 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 21 | 21 | 21 | 21 |
| Mean Estimate | -0.32 | -0.26 | -1.12 | -0.13 |
| High Estimates | -0.16 | -0.10 | -0.38 | 1.51 |
| Low Estimate | -0.49 | -0.60 | -2.19 | -2.02 |
| Coefficient of Variance | -24.70 | -36.09 | -30.85 | -589.07 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 2 | 3 | 12 |
| OVERWEIGHT | 0 | 0 | 2 |
| HOLD | 19 | 18 | 7 |
| UNDERWEIGHT | 0 | 0 | 0 |
| SELL | 0 | 0 | 1 |
| MEAN | Hold | Hold | Overweight |
SEC Filings for Apellis Pharmaceuticals Inc - APLS
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Apellis Pharmaceuticals Inc - APLS
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Mar 4, 2026 | Mikael Dolsten Director | 14,312 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 4, 2026 | Mikael Dolsten Director | 24,135 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jan 16, 2026 | Pascal Deschatelets Chief Scientific Officer | 1,158,219 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $22.19 per share | 25,700,879.61 |
| Jan 16, 2026 | Nur Nicholson Chief Technical Officer | 81,046 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $22.19 per share | 1,798,410.74 |
| Jan 16, 2026 | Mark DeLong Chief Business & Strat Officer | 83,058 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $22.19 per share | 1,843,057.02 |
| Jan 16, 2026 | David O. Watson General Counsel | 98,838 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $22.19 per share | 2,193,215.22 |
| Jan 16, 2026 | James G. Chopas VP/Chief Accounting Officer | 52,595 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $22.19 per share | 1,167,083.05 |
| Jan 16, 2026 | Timothy Eugene Sullivan Chief Financial Officer | 107,080 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $22.19 per share | 2,376,105.20 |
| Jan 16, 2026 | Cedric Francois Chief Executive Officer; Director | 321,419 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $22.19 per share | 7,132,287.61 |
| Sep 11, 2025 | Timothy Eugene Sullivan Chief Financial Officer | 60,396 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $27.83 per share | 1,680,820.68 |
| Sep 11, 2025 | Timothy Eugene Sullivan Chief Financial Officer | 242,903 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Sep 11, 2025 | Timothy Eugene Sullivan Chief Financial Officer | 110,936 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $27.86 per share | 3,090,676.96 |
| Sep 4, 2025 | Kelley Boucher Chief People Officer | 97,658 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Sep 4, 2025 | Kelley Boucher Chief People Officer | 45,766 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Sep 3, 2025 | Leslie Meltzer Chief Research and Development | 61,804 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Sep 3, 2025 | Leslie Meltzer Chief Research and Development | 92,592 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jun 12, 2025 | Caroline Baumal Chief Medical Officer | 82,500 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| May 23, 2025 | Pascal Deschatelets Chief Scientific Officer | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |